MEDICAL CHANNEL ASIA

PUBLIC PORTAL

PUBLIC PORTAL

MEDICALLY REVIEWED

FDA approves lenacapavir (Sunleca®) in heavily pre-treated adults with multi-drug resistant HIV-1 infection

Lenacapavir, HIV

Lenacapavir (Sunleca®), a first-in-class long-acting HIV-1 capsid function inhibitor, was approved by the FDA in December 2022 . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: